Ex­clu­sive: As­traZeneca’s out­go­ing R&D chief Mene Pan­ga­los re­flects on a 14-year R&D turn­around and the in­dus­try's fu­ture

When As­traZeneca R&D ex­ec­u­tive Mene Pan­ga­los joined the com­pa­ny in 2010, the UK drug gi­ant was fac­ing ex­is­ten­tial threats: shrink­ing sales, a meek pipeline and a takeover at­tempt by Pfiz­er.

Pan­ga­los saw the biggest prob­lem: As­traZeneca’s re­search wasn’t de­liv­er­ing. As­traZeneca had a 4% suc­cess rate in bring­ing drugs through Phase III, trail­ing a 6% in­dus­try av­er­age. He pushed a new fo­cus on qual­i­ty over quan­ti­ty that, from 2012 to 2016, drove As­traZeneca’s suc­cess rate to 19% — even as the in­dus­try av­er­age fell to 4%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER